Summit Financial’s Avadel Pharmaceuticals AVDL Stock Holding History

Summit Financial’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-33,851	Closed	-$729K	–	1404
2025 Q4	$729K	Sell	33,851 -1,608	-5%	-$31.2K	0.01%	769
2025 Q3	$541K	Sell	35,459 -33,773	-49%	-$439K	0.01%	864
2025 Q2	$613K	Buy	+69,232	New	+$608K	0.01%	529

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Summit Financial's AVDL Position: Q1 2026 in Review

Summit Financial sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 33,851 shares — an estimated $729K sold.

Summit Financial first reported a position in AVDL in Q2 2025 and held it in 3 quarters. The position peaked at $729K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Summit Financial reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Summit Financial sold 33,851 Avadel Pharmaceuticals shares in Q1 2026, an estimated $729K.
Summit Financial first reported a position in Avadel Pharmaceuticals in Q2 2025 and held it in 3 quarters.
Summit Financial's Avadel Pharmaceuticals position peaked at $729K in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Summit Financial's 13F filing for Q1 2026, filed 15 May 2026.